Human papillomavirus vaccines: Challenges to implementation

Sexual Health

Volumn 3, Issue 2, 2006, Pages 63-65

  Garland, Suzanne M ^a,b  

^a ROYAL WOMEN'S HOSPITAL   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

WART VIRUS VACCINE;

AUSTRALIA; COST; CYTOLOGY; DRUG EFFICACY; EDUCATION; HUMAN; IMMUNE RESPONSE; INFECTION; MEDICAL PROFESSION; PAPANICOLAOU TEST; REVIEW; UTERINE CERVIX CANCER; VACCINATION;

CLINICAL TRIALS; CLINICAL TRIALS AS TOPIC; FEMALE; HEALTH EDUCATION; HUMANS; MALE; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; UTERINE CERVICAL DISEASES; UTERINE CERVICAL NEOPLASMS; VACCINATION; VIRAL VACCINES;

EID: 33744785703     PISSN: 14485028     EISSN: None     Source Type: Journal    
DOI: 10.1071/SH06018     Document Type: Review

References (15)

1. Koutsky LA, Ault KA, Wheeler CM, Brown DR, Barr E, Alvarez FB, et al. Proof of Principle Study Investigators. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med 2002; 347(21): 1645-51. doi: 10.1056/NEJMoa020586
2. Mao C, Koutsky L, Ault K, Wheeler C, Brown D, Wiley D, et al., for the Proof of Principle Study Investigators. Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia. A randomised controlled trial. Obstet Gynecol 2006; 107(1): 18-27.
3. Harper DM, Franco EL, Wheeler C, Ferris DG, Jenkins D, Schuind A, et al., and the GlaxoSmithKline HPV Vaccine Study Group. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 2004; 364(9447): 1757-65. doi: 10.1016/S0140-6736(04)17398-4
4. Villa LL, Costa RL, Petta CA, Andrade RP, Ault KA, Giuliano AR, et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16 and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 2005; 6(5): 271-8. doi: 10.1016/S1470-2045(05)70101-7
5. Skjeldestad F for the FUTURE II Steering Committee; Dept of Epidemiology, SINTEF Health Research, Trondheim, Norway. Prophylactic Quadrivalent Human Papillomavirus (HPV) (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine (Gardasil™) Reduces Cervical Intraepithelial Neoplasia (CIN) 2/3 Risk. Abstract 43rd Annual Meeting of Infectious Diseases Society of America, October 6-9, 2005, San Francisco, CA. [Abstract]
6. Harper D. for the FUTURE I investigators. Efficacy of a Prophylactic Quadrivalent Human Papillomavirus (HPV) (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine for Prevention of Cervical Dysplasia and External Genital Lesions (EGL) 45th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy, December 16-19, 2005, Washington, DC.
7. Smith AMA, Rissel CE, Richters J, Grulich AE, de Visser RO. Sex in Australia: first experiences of vaginal intercourse and oral sex among a representative sample of adults. Aust N Z J Public Health 2003; 27(2): 131.
8. McClelland A, Liamputtong P. Knowledge and acceptance of human papillomavirus vaccination: perspectives of young Australians living in Melbourne, Australia. Sex Health 2006; 3(2): 95-102. doi: 10.1071/SH05035
9. Giles M, Garland SM. A study of women's knowledge regarding human papillomavirus virus (HPV) infection, cervical cancer and HPV vaccines. ANJOG 2006.
10. Australian Institute of Health and Welfare (AIHW) Cervical Screening in Australia 2002-2003. AIHW Cat. No. 26. Canberra: Australian Institute of Health and Welfare; 2005. (Cancer Series Number 31).
11. Australian Institute of Health and Welfare (AIHW). Cervical screening in Australia 2000-2001 and 1999-2000. AIHW Cat. No. 19. Canberra: Australian Institute of Health and Welfare; 2003. (Cancer Series Number 24).
12. Goldie SJ, Kohli M, Grima D, Weinstein MC, Wright TC, Bosch FX, Franco E. Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine. J Natl Cancer Inst 2004; 96(8): 604-15.
13. Kulasingam SL, Myers ER. Potential health and economic impact of adding a human papillomavirus vaccine to screening programs. JAMA 2003; 290(6): 781-9. doi: 10.1001/jama.290.6.781
14. O'Keefe E, Currie MJ, Garland SM, Tabrizi S, Bowden FJ. Prevalence of genital human papillomavirus DNA in a sample of senior school-aged women in Australian Capital Territory. Sex Health 2006; 3(2): 91-4. doi: 10.1071/SH05047
15. Medicare Australia. Australian Childhood Immunisation Register Statistics. Coverage. Available online at: www.medicareaustralia. gov.au/providers/health_statistics/statistical_reporting/acir.htm [verified May 2006].